AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - New Scientist UK Edition)
Zurich-based Cytos Biotechnology is developing CYT003-QbG10, a treatment for allergy patients which tricks the body into believing that it is being harmed by mycobacteria. Instead of producing an allergic reaction to harmless substances such as grass pollen, the immune system focuses on dealing with a perceived larger threat. Preliminary trials on ten hay fever sufferers showed that …